A Na-eme Ka Mgbochi Ọrịa HIV Gaa na Nhọrọ Nke Mbụ Nhọrọ na US
Tivicay (dolutegravir) bụ onye na- eme ihe na-eme ihe na-eme ka a ghara iji ọgwụ nje eme ihe. Ọ bụ nke abụọ na klas nke ndị na-eme ihe nchịkọta nke ndị United States Food and Drug Administration (FDA) kwadoro.
E nyere Tivicay ikikere FDA n'ọnwa Ọgọst 12, 2013, maka ndị okenye na ụmụaka dị afọ iri na abụọ ma ọ bụ karịa, ndị na-atụ egwu ma ọ dịkarịa ala 88 lbs (40kg) na-emebeghị ihe na-eme ihe.
(Tivicay adịghị akwadoro ugbu a maka ụmụaka dị afọ iri na abụọ ọ bụ ezie na ọnwụnwa nke usoro Phase nke atọ na-aga n'ihu iji chọpụta nchedo na nrụpụta ọrụ ya n'oge ahụ.)
Tivicay bụkwa otu ihe na-eme kwa ụbọchị, ọgwụ na-ejikọta ọnụ, Triumeq , nke gụnyere ọgwụ abacavir na lamivudine. FDA kwadoro nkeji ato na August 22, 2014.
Ihe omuma nke ulo ogwu
Nyocha VIKING-3 gosiri na Tivicay dị irè n'ime pasent 63 nke ndị okenye na-eguzogide ọtụtụ klas nke ọgwụ nje HIV, gụnyere ndị na-eme ihe ntinye aka na-emepụta ihe (Isinress) (ratelgravir) na elvitegravir (dị na otu mkpụrụ ọgwụ, .
Ihe omumu nke a gosiri na ndị ọrịa nọ na Tivicay nwere ntakịrị ihe mgbochi maka ọgwụ ọjọọ karịa Atripla (tenofovir + emtricitabine + efavirenz). Mgbe izu 48 gasịrị, 2% nke isiokwu ndị dị na usoro Tivicay kwụsịrị ịgwọ ọrịa na pasent 10 nke ndị na-anata Atripla.
Ọgwụgwọ
- Ndị okenye: 50mg mbadamba, otu ugboro kwa ụbọchị
- Ndị okenye nwere nguzogide ndị na-arụ ọrụ na-arụ ọrụ : 50mg mbadamba, ugboro abụọ kwa ụbọchị
- Ụmụaka 12 na karịa (na-erukwa 88 lbs / 40kg ma ọ bụ karịa): 50mg mbadamba, otu ugboro kwa ụbọchị
Tụkwasị na nke a, maka ụmụaka ndị na-elekọta Sustiva (efavirenz), Aptivus (tipranavir) + Norvir (ritonavir), Lexiva (fosamprenavir) + Norvir (ritonavir), ma ọ bụ rifampin, dose Tivicay bụ 50mg, ugboro abụọ kwa ụbọchị.
A maghị Tivicay ma ọ bụrụ na Tivicay dị irè na ụmụ nwere mmegide na-emegide onye na-emechi ihe.
Nchịkọta Ọgwụ
Enwere ike iji ọgwụ na-eri nri ma ọ bụ na-enweghị nri, n'oge ọ bụla n'ụbọchị.
Mmetụta Na-agakarị
Ihe kachasị emetụtakwa (nke mere na 2% ma ọ bụ obere nke ikpe) bụ:
- Mkpụrụ obi
- Isi ọwụwa
- Dizziness
- Nausea
Mmekọrịta ọgwụ ọjọọ ma ọ bụ nkwekọrịta
Tikosyn (dofetilide), nke a na-eji na-agwọ ọrịa arrhythmia (obi mgbawa oge ụfọdụ), na-emegide ya maka Tivicay.
Iji zere mmekọrịta ọgwụ ọjọọ na-eme, kọọ dọkịta gị na ị na-ewere ọgwụ ọ bụla ma ọ bụ mgbakwunye:
- Ọgwụgwọ Antiretroviral : Sustiva (efavirenz), Integrity (etravirine), Viramun (nevirapine), yana njikọta nke Lexiva (fosamprenavir) + Norvir (ritonavir), ma ọ bụ Aptivus (tipranavir) + Norvir (ritonavir)
- Ngwá ọgwụ ngbochi: Trileptal (oxcarbazepine), Dilantin (phenytoin), Phenytek (phenytoin), Luminal (phenobarbital), ma ọ bụ ọgwụ ndị carbamazepine dịka Carbatrol, Equetro, Tegretol, Teril, ma ọ bụ Epitol
- Ngwọrọgwu Rifampin dabeere na Rifampin: Rifadan, Rifater, Rifamate, Rimactane
- Mmiri ịrịa ọrịa shuga na Metformin: Fortamet, Glucophage, Glumetza, Riomet
- John Wort
Echiche
- Ndị ọrịa nwere ahụmahụ nhụsịrị ahụ mgbe ha malitere Tivicay kwesịrị ịkpọtụrụ dọkịta ha ozugbo . A ghaghị ịkwụsị ọgwụgwọ ma gwọọ ọgwụgwọ ma ọ bụrụ na ọkụ ọkụ na-esonyere ya na ahụ ọkụ, nkwonkwo ma ọ bụ nkwonkwo ahụ, ọnyá ma ọ bụ ọnyá, ọbara ọbara ma ọ bụ ọzịza nke anya, ikpu nke ihu ma ọ bụ ọnụ, ma ọ bụ nsogbu iku ume. Ọrịa ndị na-ahụtụbeghị mbụ na Tivicay nwere ike ekwesighi ka a kọwaa ya ọzọ na ọgwụ ahụ mgbe ọ na-edozi ihe mgbaàmà.
- Ekwesịrị iji ihe dịka elekere abụọ tupu ma ọ bụ awa isii mgbe ị gbasịrị aluminum - ma ọ bụ magnetium nke nwere antacids ma ọ bụ laxatives, mgbakwunye ígwè, nchịkọta calcium, ọgwụ mgbochi, ma ọ bụ Carafate (sucralfate) iji na-agwọ ọnya duodenal.
- Gwa dọkịta gị banyere ọnọdụ umeji ọ bụla i nwere tupu ịmalite Tivicay. Enwere ike inwe ihe ize ndụ dị ukwuu maka nsogbu imeju ụfọdụ, karịsịa maka ndị nwere ịba ọcha n'anya B (HVB), ịba ọcha n'anya C (HCV) , ma ọ bụ nkwarụ nke imeju oge. A na-enyocha enzymes imeju anya dịka akụkụ nke ihe nyocha nke ọbara na- ewe Tivicay.
> Isi mmalite:
National Library of Medicine. "TIVICAY (dolutegravir sodium) mbadamba nkume, nke a kpochara ihe nkiri." Bethesda, Maryland; emegharịrị August 2013.
Ahụike ViiV. "Ahụike ViiV na-enweta nkwado FDA maka Triumeq." London, England; pịa ntọhapụ nyere 22 August 2014.
Walmsley S .; Antela, A .; Clumeck, N .; et al. "Dolutegravir (DTG; S / GSK1349572) + abacavir / lamivudine otu ugboro kwa ụbọchị kwa ụbọchị karịa tenofovir / emtricitabine / efavirenz: izu 48-izu - SINGLE (ING114467)." 52th Conference Concescience on Antimicrobial Agents na Chemotherapy. San Francisco; Septemba 9-12, 2012; Ihe omuma H-556b.
Nichols, G .; Grossberg, R .; Lazzarin, A .; et al. "Antiviral Ọrụ nke Dolutegravir na Ndị Na-achịkwa Na-enweghị ihe Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results From VIKING-3." 11th International Congress on Medicinal Drug in HIV HIV (HIV11). Glasgow, Scotland; November 11-15, 2012; Abstract O232.